אבירטרון תרו 250 מ"ג - Abiraterone taro 250 mg

× ×ª×× × ×ª×¨××¤×

××× ×× ×× × ××¡×¤××	××××¨××¨×× ××¡.×§×× 250 ×"× - Abiraterone S.K 250 mg ××××¨××¨×× ×ª×¨× 500 ×"× - Abiraterone taro 500 mg ××××¨××¨×× - ×ª×¨××× 250 ×"× - Abiraterone - trima 250 mg ××××¨××¨×× ×××¢ 250 ×"× - Abiraterone teva 250 mg ××××¨××¨×× ×××¢ 500 ×"× - Abiraterone teva 500 mg ××××¨××¨×× ××××× 250 ×"× - Abiraterone medomie 250 mg ××××¨××¨×× ××××× 500 ×"× - Abiraterone medomie 500 mg ××××¨××¨×× ×¡× ××× 250 ×"× - Abiraterone sandoz 250 mg ××××¨××¨×× ×¡× ××× 500 ×"× - Abiraterone sandoz 500 mg
×§×××¦× ×¤×¨××§××××××ª (ATC4)	L02BX Other hormone antagonists and related agents
××¨××× ×¤×¢×× (ATC5)	Â Abiraterone ACETATE 250 MG âL02BX03
×¦××¨×ª ××ª×	×¤××× - PER OS
×¦××¨×ª ××× ××	××××××ª ××¦××¤××ª ×¤×××, FILM COATED TABLETS ××× ××¢×ª ××× ×× ××ª×¨ ×× ××¨×¢×× ××© ××××× ××ª ××ª×¨××¤× ×××ª×× ×××× ×× ××××××¥ ××¤× ×©×××¤××¢ ××¢××× ××¦×¨××
××ª××××	Abiraterone Taro is a CYP17 inhibitor indicated:- in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.- for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).
×¢××× ××¨××¤× ×××××¨××ª ××¢×××	Â ××× ×¢××× ××¨××¤× Â

×¢××× ××¦×¨××	Â

×¢×¨××× ×××××§××¨×¤×××	×¢×¨××× ×§×©××¨×× ×××××§××¨×¤×××
××××¨××¨×× ×ª×¨× 250 ×"× ×××××¨ ××©×¨× ×××¨××××ª

×××¤××© ××××¨××	××××¨×× ×-PubMed
××××¢ ××¨×©×ª	RxList WebMD Drugs.com
×©× ××¦×¨×	REMEDICA LTD., CYPRUS
×©× ××¢× ××¨××©××	TARO INTERNATIONAL LTD, ISRAEL
×¨××©×××	×ª××¨×× ×××©×: 3/2022. ×¨××©××× ××ª××¨××:
×ª××¨×× ×¢×××× ×××¨××	09/11/2024

השינוי האחרון נעשה בֹ־9 בנובמבר 2024 ב־08:20